Abstracts Archive - Page 206 of 2607 - ACR Meeting Abstracts

Abstract Number: 2694 • ACR Convergence 2024
Associations Between Immune Checkpoint Molecules and Nasal Microbiome in ANCA-associated Vasculitis
Yoichi Nakayama¹, Mirei Shirakashi², Erika Furukawa³, Chikako Endo⁴, Tsuneo Sasai⁵, Yuya Tabuchi⁴, Ryosuke Hiwa⁵, Hideaki Tsuji⁵, Koji Kitagori⁶, Shuji Akizuki⁷, Ran Nakashima⁵, Kosaku Murakami³, Hajime Yoshifuji⁵ and Akio Morinobu⁸, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ³Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶Occupational Welfare Division, Agency for Health, Safety and Environment, Kyoto University,, Kyoto, Kyoto, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Among patients with ANCA-associated vasculitis (AAV), several exhibit sinonasal involvement, especially in granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA). A recent…
Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
Abstract Number: 2574 • ACR Convergence 2024
Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children
Mariia Pavlenko¹, Ilaria Maccora², Mekibib Altaye³, hermine brunner⁴, Alexandra Duell³, Megan Quinlan-Waters³, Alyssa Sproles¹, Sherry Thornton⁵, Virginia Miraldi Utz³ and sheila Angeles-Han⁶, ¹Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Childhood chronic anterior uveitis (CAU) can be idiopathic (iCAU) or associated with Juvenile Idiopathic Arthritis (JIA-U). Ocular complications occur in 50% of affected children. …
Abstract Number: 2594 • ACR Convergence 2024
A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Saul Kivimae¹, Sandip Mukherjee², Phi Quach³, Rhoneil Pena⁴, Olga Zemska³, Michal Olszewski⁵, Jicai Huang³, Michael Labson⁶, Donald Walker¹, Mekhala Maiti⁷, Chakrapani Tripathi⁸, Thomas Chang³, Suresh Adapala⁹, Damon Hamel³, Katherine Brendza³, Takahiro Miyazaki³ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Francisco, ³Nektar Therapeutics, San Francisco, ⁴Sutro Biopharma, South San Francisco, ⁵Vaxcyte, San Francisco, ⁶Guardant Health, Palo Alto, ⁷Alumis, Inc, South San Francisco, ⁸Theragent Inc, Arcadia, CA, ⁹Inotiv, Rockville, MD
Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…
Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Robert Fearon, Sjögren's Foundation, Reston, VA
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…
Abstract Number: 2604 • ACR Convergence 2024
Altered Expression of Ecto-5′-Nucleotidase (NT5E) in SLE Patients Based on Disease-associated Genotype
Mikhail Olferiev¹, Katherine Owen², Peter Lipsky³ and Mary Crow¹, ¹Hospital for Special Surgery, New York, NY, ²RILITE, Charlottesville, VA, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: The NT5E gene, encoding Ecto-5'-Nucleotidase/CD73, is expressed on the surface of immune system cells and is critical for converting AMP/IMP to adenosine/inosine, important immunosuppressive purine nucleosides.…
Abstract Number: 2600 • ACR Convergence 2024
Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus
Qiaolin Wang¹, Yutong Wu², Qianjin Lu¹ and Ming Zhao¹, ¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic), ²Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Nanjing, China (People's Republic)
Background/Purpose: Dysregulation of intestinal γδT cells orchestrates the pathogenesis of various autoimmune disorders, however, its involvement in systemic lupus erythematosus (SLE) etiology remains elusive.Methods: Employing single-cell sequencing, we…
Abstract Number: 2575 • ACR Convergence 2024
Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?
Paola Vidal¹, Javier Narvaez-García², Francesc-Xavier Fulladosa², Francesca Mitjavila², olga Capdevila², Pol Maymó³, Judith Palacios⁴ and Joan Miquel Nolla², ¹Hospital Universtiario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 2568 • ACR Convergence 2024
Incidence of First Fracture in RA Is Increasing Faster Than the General Population
Owen Taylor-Williams¹, Charles Inderjeeth² and Johannes Nossent³, ¹University of Western Australia, Perth, Western Australia, Australia, ²SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, ³University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Background/Purpose: We aim to better understand osteoporotic fracture epidemiology in rheumatoid arthritis (RA) in a West Australian (WA) RA population. We hypothesized increased availability of…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…
Abstract Number: 2453 • ACR Convergence 2024
Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study
Elvira Lesmana¹, Ashley Keehn², Anukul Karn³, Andrea Pauly⁴, Margaret Breen-Lyles², Adam L Edwinson², Madhusudan Grover⁵ and Ashima Makol⁵, ¹Mayo Clinic, Rochester, MN, New York, NY, ²Mayo Clinic, Rochester, MN, Rochester, ³Mayo Clinic, Rochester, MN, Farmington Hills, MI, ⁴Mayo Clinic Rochester, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogeneous, multisystem autoimmune disease with high morbidity and mortality. Gastrointestinal symptoms impact more than 90% of SSc patients,…
Abstract Number: 2595 • ACR Convergence 2024
TGF-β Activated Kinase 1 (TAK1) Inhibition Suppresses Synovial Inflammation and Tissue Destruction Mediated by Activated Juvenile Idiopathic Arthritis Synovial Fibroblasts
Meena Afroze Shanta¹, Paul Panipinto², Anil Singh³, Peter Nigrovic⁴, Lauren Henderson⁵ and Salahuddin Ahmed³, ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, ³Washington State university, Spokane, WA, ⁴Boston Children's Hospital, Brookline, MA, ⁵Boston Children's Hospital, Watertown, MA
Background/Purpose: Synovial inflammation is a common manifestation of juvenile idiopathic arthritis (JIA), often accompanied by debilitating synovial hyperplasia. The current study aims to characterize the…
Abstract Number: 2602 • ACR Convergence 2024
Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus
Caseng Zhang¹, Nicholas Gold², Raffaella Carlomagno³, JingJing Cao⁴, Daniela Dominguez⁴, Dafna Gladman⁵, Mariko Ishimori⁶, Caroline Jefferies⁷, Diane Kamen⁸, Sylvia Kamphuis⁹, Marisa Klein-Gitelman¹⁰, Andrea Knight¹¹, Chia-Chi Lee¹², Deborah Levy², Lawrence Ng², Karen Onel¹³, Andrew Paterson⁴, Christine Peschken¹⁴, Janet Pope¹⁵, Earl Silverman¹⁶, Zahi Touma¹⁷, Murray Urowitz¹⁸, Daniel Wallace¹⁹, Joan Wither²⁰ and Linda Hiraki², ¹University of Ottawa, Ottawa, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Lausanne University Hospital, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Beverly Hills, CA, ⁸Medical University of South Carolina, Charleston, SC, ⁹Erasmus University Medical Center, Rotterdam, Netherlands, ¹⁰Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹¹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹²Cedars-Sinai Medical Center, Los Angeles, CA, ¹³HSS, New York, NY, ¹⁴University of Manitoba, Winnipeg, MB, Canada, ¹⁵University of Western Ontario, London, ON, Canada, ¹⁶Silverman, Toronto, ON, Canada, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸Self employed, Toronto, ON, Canada, ¹⁹Cedars Sinai Medical Center, Studio City, CA, ²⁰University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease with multi-organ involvement and a strong female predominance. Prior studies demonstrated sex dimorphism in…
Abstract Number: 2451 • ACR Convergence 2024
Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients
Chiara Bellocchi¹, Alessandro Santaniello², Silvia Bosello³, Enrico De Lorenzis⁴, Gerlando Natalello⁵, Nicoletta Del Papa⁶, Silvia Cavalli⁷, Devis Benfaremo⁸, Giacomo De Luca⁹, Corrado Campochiaro¹⁰, Lorenzo Cavagna¹¹, Veronica Codullo¹², Francesco Bonomi¹³, gaia Montanelli¹⁴, Adriana Severino¹⁵, Monica Caronni², Martina Iacubino¹⁶, Barbara Vigone², Silvia Bellando-Randone¹⁷, Carlomaurizio Montecucco¹⁸, Marco Matucci-Cerinic¹⁹, Lorenzo Dagna²⁰, Gianluca Moroncini⁸, Roberto Caporali²¹ and Lorenzo Beretta²², ¹Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, MILANO, Italy, ³FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI- IRCCS, Rome, Rome, Italy, ⁴Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁶ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy, ⁷University of Milan, Milan, Milan, Italy, ⁸Marche Polytechnic University, Ancona, Italy, ⁹Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹¹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ¹²Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ¹³Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Milan, Italy, ¹⁶Università degli Studi di Milano, Milano, Italy, ¹⁷University of Florence, Florence, Florence, Italy, ¹⁸IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ¹⁹University San Raffaele Milano, Milano, Milan, Italy, ²⁰Ospedale San Raffaele, Milano, Italy, ²¹Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Pulmonary function tests (PFTs) can serve as useful surrogate measures…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].